Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Married patients with locally advanced lung cancer likely to survive longer after treatment

Married patients with locally advanced lung cancer are likely to survive longer after treatment than patients who are single, according to a study by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.

7 Sep 2012

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Race, marital status can impact survival rates of patients with Stage III non-small cell lung cancer

A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

7 Sep 2012

Scientists complete comprehensive map of genetic mutations linked to small cell lung cancers

Scientists have completed a comprehensive map of genetic mutations linked to an aggressive and lethal type of lung cancer.

6 Sep 2012

More women and non-smokers being diagnosed with non-small cell lung cancer

There has been an increase in the number of non-smokers being diagnosed with non-small cell lung cancer, according to new findings.

5 Sep 2012

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

24 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Increases in NSCLC survival 'an artefact of PET assessment'

There has been no increase in survival among non-small-cell lung cancer patients in recent years, with evidence suggesting otherwise likely due to positron emission tomography-induced stage migration and selection bias, say US scientists.

8 Aug 2012

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Fit older adults with locally advanced non-small-cell lung cancer reap similar benefit from concurrent chemoradiation with etoposide and cisplatin as younger patients, but experience higher rates of hospitalization and toxicity, research shows.

8 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Six hospitals join CoC ProvenCare Lung Cancer Collaborative

Six more hospitals have joined a national pilot study already under way to promote evidence-based evaluation and treatment standards for patients with non-small cell lung cancer (NSCLC). Patients with this type of lung cancer are also candidates for an operation called "lung resection."

2 Aug 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Small Cell Lung Cancer News and Research

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Married patients with locally advanced lung cancer likely to survive longer after treatment

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Race, marital status can impact survival rates of patients with Stage III non-small cell lung cancer

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Scientists complete comprehensive map of genetic mutations linked to small cell lung cancers

More women and non-smokers being diagnosed with non-small cell lung cancer

Results from Biodesix VeriStrat phase II advanced lung cancer trials

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Increases in NSCLC survival 'an artefact of PET assessment'

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Folate, excision biomarkers not predictive for small-cell lung cancer response

GTx reports revenue of $1.6 million for second quarter 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Six hospitals join CoC ProvenCare Lung Cancer Collaborative

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Potential biomarker to predict lung cancer patients' response to chemotherapy

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News